Market cap is the total market value to buy the whole company. It is equal to the share price times the number of Shares Outstanding (EOP). Financiere de Tubize's share price for the quarter that ended in Dec. 2023 was €71.7377. Financiere de Tubize's Shares Outstanding (EOP) for the quarter that ended in Dec. 2023 was 44.51 Mil. Therefore, Financiere de Tubize's market cap for the quarter that ended in Dec. 2023 was €3,193.23 Mil.
Financiere de Tubize's quarterly market cap
increased
from Dec. 2022 (€3,149.40 Mil) to Jun. 2023 (€3,160.39 Mil) and
increased
from Jun. 2023 (€3,160.39 Mil) to Dec. 2023 (€3,193.23 Mil).
Financiere de Tubize's annual market cap
declined
from Dec. 2021 (€4,046.20 Mil) to Dec. 2022 (€3,149.40 Mil) but then
increased
from Dec. 2022 (€3,149.40 Mil) to Dec. 2023 (€3,193.23 Mil).
Enterprise Value is the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents. Financiere de Tubize's Enterprise Value for Today is €4,743.55 Mil.
Financiere de Tubize Market Cap Historical Data
The historical data trend for Financiere de Tubize's Market Cap can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Financiere de Tubize's Market Cap
For the Biotechnology subindustry, Financiere de Tubize's Market Cap, along with its competitors' market caps and Market Cap data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Financiere de Tubize's Market Cap Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Financiere de Tubize's Market Cap distribution charts can be found below:
* The bar in red indicates where Financiere de Tubize's Market Cap falls into.
Financiere de Tubize Market Cap Calculation
Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.
Financiere de Tubize's Market Cap for the fiscal year that ended in Dec. 2023 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Financiere de Tubize (LTS:0D53) Market Cap Explanation
Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the companys debt. The real price you pay is the Enterprise Value.
Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.
Financiere de Tubize Market Cap Related Terms
Thank you for viewing the detailed overview of Financiere de Tubize's Market Cap provided by GuruFocus.com. Please click on the following links to see related term pages.
Financiere de Tubize (LTS:0D53) Business Description
Financiere de Tubize SA is a holding company that owns a stake in UCB, a biopharmaceutical company. UCB is a global biotechnology company that develops treatments for conditions related to neurology and immunology. UCB generates the vast majority of its revenue in the United States, followed by Europe and other international markets. Most of its sales revenue is derived from its neurology products, followed by its immunology products. The company's strategy focuses on leveraging scientific advances and skills in areas such as genetics, biomarkers, and human biology.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
LTS:0D53 has been successfully added to your 